Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.78B 10.19B 9.52B 8.73B 16.42B 1,122B 16.69B 112B 43.83B 562B 44.25B 43.28B 1,858B P/E 2026 *
-80.8x
P/E 2027 * 81x
Enterprise Value 11.26B 9.74B 9.1B 8.34B 15.69B 1,072B 15.94B 107B 41.88B 537B 42.28B 41.36B 1,776B EV / Sales 2026 *
7.38x
EV / Sales 2027 * 5.05x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.06%
1 week+9.14%
Current month+9.14%
1 month-6.48%
3 months-4.64%
6 months+6.79%
Current year-12.42%
1 week 461.25
Extreme 461.25
524.45
1 month 447.01
Extreme 447.01
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 342.73
Extreme 342.733
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 7.27
Extreme 7.27
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Director

1,220 0.0053%
23/2/26 Fiscal year

Director

5,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%+9.14%+49.01%+184.16% 11.78B
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.45%+11.43%+52.52%+204.71% 27.53B
Weighted average by Cap. +4.17%+12.93%+49.46%+169.16%

Financials

2026 *2027 *
Net sales 1.53B 1.32B 1.23B 1.13B 2.13B 145B 2.16B 14.47B 5.68B 72.81B 5.73B 5.61B 241B 2.14B 1.86B 1.73B 1.59B 2.99B 204B 3.04B 20.33B 7.98B 102B 8.05B 7.88B 338B
Net income -184M -159M -149M -136M -256M -17.5B -260M -1.74B -684M -8.77B -690M -675M -29B 200M 173M 162M 148M 279M 19.03B 283M 1.9B 744M 9.54B 751M 735M 31.54B
Net Debt -525M -454M -424M -389M -731M -49.92B -743M -4.97B -1.95B -25.02B -1.97B -1.93B -82.72B -943M -816M -762M -699M -1.31B -89.77B -1.34B -8.94B -3.51B -44.99B -3.54B -3.46B -149B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
07/08/26 USD 510.04 -0.06% 347,529
06/08/26 USD 510.36 -0.73% 296,763
05/08/26 USD 514.12 +1.29% 349,534
04/08/26 USD 507.56 +5.30% 442,367
03/08/26 USD 482.00 +3.14% 463,916
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
510.04USD
Average target price
678.06USD
Spread / Average Target
+32.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock